thromboDx BV and VU University, Amsterdam, The Netherlands, have signed an exclusive world-wide license agreement on the platelet-powered diagnostics patent portfolio. thromboDx BV has licensed the intellectual property rights to a broad patent portfolio covering the use of platelets as unique source of disease specific nucleic acids. The core principle of the patent portfolio is the finding that circulating nucleic acids can be taken up by blood platelets, providing a safe-haven to the nucleic acids. thromboDx BV has an aggressive strategy in pursuing new intellectual property where and when possible. Additionally thromboDx BV has developed a large body of know-how that relates to platelet-powered diagnostics.